Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Search
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia
Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
New initiative elevates the importance of CKD testing
Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Global Careers Page | Boehringer Ingelheim
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Management Rotation | Academic Programs
Management Rotation Program
ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
Therapeutics
Therapeutics
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Financial year 2018
Financial year 2018
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Corporate Social Responsibility | Boehringer Ingelheim US
Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.
new_health_insurance_marketplace_coverage_options_and_your_health_coverage.pdf
Our Mission
Our Story
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.
Why role models matter for black veterinarians: One doctor's story
Why role models matter for black veterinarians: One doctor's story
Meet our Team
Meet Our Team